Bayer Bids $2.4 Billion To Acquire Norwegian Biotech Partner Algeta
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer would gain full control of the potential blockbuster prostate cancer therapy, Xofigo, if successful.